SYNTHESIS OF 2-AZABICYCLO [3.3.1] NONANES.

* Joan Bosch and Josep Bonjoch. Department of Organic Chemistry, Faculty of Pharmacy, University of Barcelona, Barcelona, Spain.

All methods for the synthesis of 2-azabicyclo $\lceil 3.3.1 \rceil$ nonanes paying special attention to those which lead to functionalized systems are reviewed. This system, present in several alka loids, **is** synthetically and theoretically interesting. The synthe tic routes are classified according to the method used for the f_1 nal cyclization to the morphan system.

CONTENTS

- 1. Introduction.
- 2. First syntheses: cyclization by lactamization.
- 3. Phenylmorphans.
- 4. N-Chlaramines route.
- 5. Intramolecular Michael-type cyclizatian.
- 6. Other syntheses with formation **of** piprridine ring in the **last** stage.
- 7. Formation of carbocyclic ring in the last stcp: Dieckmann cyclization.
- 1. Introduction.

2-AZABICYCLO 3.3.1 NONANE

The 2 -azabicyclo^[3.3.1]nonane system¹ is present in many compounds, both natural and synthetic ones. This grouping occurs in morphine², the main opium alkaloid, as well as in a great number of heterogeneous indole alkaloids³, such as the strychnos alkaloids (strychnine, tubifoline, condyfoline), the picralime alkaloids (akuammine, akuammicine), the aspidospermum alkaloids (uleine, dasycarpidone), and the geissaspermum alkaloids (geissoschizoline); it is also present in some calabash curare alkaloids as fluarocurarine.

Among the synthetic molecules containing the 2-azabicyclo^[3.3.1]nonane nu cleus, morphinans⁴ (e.g. levorphanol) and 6,7-benzomorphans^{4,5} (e.g. pentazocine) are specially interesting since they are strong synthetic analgesics. Heteromorphans 6 , bioisosters of 6,7-benzomorphans, in which the benzene ring is substituted by an heteroaromatic ring are also included. In the last years, some thieno- $6-9$, benzo[b]thieno- 10 , pyrido- $^{11-13}$, indolo- 14 , 15, furo- 16 , and pyrrolomorphans¹⁷ have been described.

Other compounds including the **2-azabicyclo[3.3.l]nonane** system are the structurally interesting 2-azaadamantane¹⁸, some cyclohex[j](and[d]) indolo[2,3-f] morphans $19-21$, of interest in biogenetic type syntheses of indole analogues of mor phine alkaloids, and same **methanobenzofuro[3,2-dIazocine5** prepared as transformation products of thebaine²².

The systems of **2-azabicyclo[3.3.l]nonane,** especially the functionalized ones, are of great interest for the study of some structure-reactivity relationships and for being intermediates in the synthesis of more complex structures.

In the fleld of structural chemistry, **2-azabicyclo[3.3.1]nonanes** allow to extend the studies, now in rapid developing, which are carried out with their carbocyclic analogues, bicyclo^[3.3.1]nonanes^{23,24}. Thus, through these type of bridged systems, the reach of the Bredt's rule²⁵ was studied, the bicyclo^[3.3.1]non-1-ene²⁶ and its corresponding 2-aza analogue²⁷ were synthesized and their unusual reactivi ty was examined^{26,27}. The conformational analysis^{28,29} and the stability of noneno lizable 1,3-dicarbonyl derivatives of these systems³⁰ are further aspects of their structural interest.

In the field of organic synthesis, functionalized 2-azabicyclo $\lceil 3.3.1 \rceil$ nona nes have been used as intermediates in the preparation of model structures related to natural products, especially of indole alkaloids³¹, and as precursors of complex polycyclic systems 32 . They have also been used as intermediates in the preparation of potentially active systems from the pharmacological standpoint^{12,33}. In this as pect some **2-azabicyclo[3.3.l]nonanes** are themselves interesting, just as it happens with 5 -phenylmorphans³⁴, strong analgesics. Moreover, the study of the structureactivity relationships in synthetic analgesics has been enlarged through them 35 .

In this review on the synthesis of **2-azabicyclo[3.3.1]nonanes** we are not going to take into account those approaches which lead to systems in which thls grou ping is part of a more complex polycyclic structure.

2. First syntheses: cyclization by lactamization.

In 1947 Barltrop³⁶ reported the first reference about 2-azabicyclo^[3.3.1] nonanes, in the context of the synthesis of cyclic ring systems ocurring in the mor phine molecule. It describes an approach to this system by alkylation of ethyl 2 oxocyclohexanecarboxylate with **2-chloroethyldiethylamine** and further cyclization through the 6-bromo derivative, to give the ammonium salt 1 in a yield lower than 1%.

The preparation of 2 -azabicyclo^[2.2.2]octane by copper chromite³⁷ reduction of the lactam of cis-4-aminocyclohexanecarboxylic acid suggested to Cronyn³⁸ that the unsubstituted **2-azabicyclo[3.3.l]nonane** *(5)* could be similarly synthesized by lactamization of **&-3-aminocyclohexaneacetic** acld (2, R=H) or of that of its *co* rresponding ester (2, $R=Et$) and subsequent reduction of the resulting lactam 4.

The synthesis was achieved from ethyl m-nitro-0-benzoylmandelate (3) using different procedures. The best one was the direct hydrogenation over Raney nickel in tert-butanol at 200°C, since in these conditions cyclization occurs and the lactam 4 was obtained in 35% of overall yield. Finally, the lactam 4 was hydrogenated to 2-azabicyclo^[3.3.1]nonane (5) over copper chromite in tert-butanol (46% yield).

A parallel synthesis of Ginsburg³⁹ introduced some variations in the experimental aspect. Thus, reduction of ethyl m-nitrophenylacetate in glacial acetic acid using Adam's catalyst gave the aminoester 2 (R=Et) in good yield, and subsequent lactamization by heating at 150°C afforded 4 in 84% yield. Final reduction to the morphan system **i** was carried out with lithium aluminum hydride. Later on, 'an analogous synthesis of 4 from m-nitrophenylacetic acid has been described^{35,40}. N-Methylation with sodium hydride and methyl iodide gave 2-methyl-2-azabicyclo^[3.3.1]nonan-3-one, and this lactam was reduced to the N-methylmorphan 6 with lithium aluminum hydride $35,40$.

In a study of **2-azabicyclo[3.3.1]non-1-ene** systems as reaction intermedia tes with a bridgehead double bond a new synthesis of the lactam 4 and of some C_1 substituted derivatives were reported²⁷. The aminoester 2 was obtained from methyl 3-oxocyclohexaneacetate through 0-methyloxime 2 and subsequent reduction and esterification. Heating of 2 in the presence of sodium methoxide afforded lactam 4 in 50.60% yield.

Treatment of 4 with lead tetraacetate **gave 1-acetoxy-3-0x0-2-azabicyclo** $\left[3.3.1\right]$ nonane $\left(9\right)$, being 2 -azabicyclo $\left[3.3.1\right]$ non-1-ene <u>8</u>-the probable intermediate. From acetoxylactam **9**, some substitution reactions at C₁-position were carried out, and 1-methoxy- and 1-cyanoderivatives were obtained, their formation involving again the presence of an imino intermediate of type 8.

Similarly, when the alkaloid methyl hamasecodaphniphyllate, which contains the **2-azabicyclo[3.3.1]nonane** system, was treated with lead tetraacetate the formation of an unusually anti-Bredt's -rule imine containing the 2-azabicyclo $\lceil 3.3.1 \rceil$ non-1-ene system was described 41 .

The preparation of 9-hydroxy-2-azabicyclo^[3.3.1]nonane⁴² is one of the few approaches to C_q -functionalized morphans, and together with the precedent one are the only ways to marphan systems which involve the formation of an amide bond at the last step without using aromatic compounds as starting materials.

From 3-carbethoxy-2-oxocyclohexaneacetic acid (10) piperidine ring was for med. Thus, the replacement of the carbethoxy group by the oximino group gave 11, which was catalytically hydrogenated affording the hydrochloride of the aminoester
12. Reduction of this hydrochloride with sodium borohydride yielded (36%) the isolable crystalline isomer ethyl c-3-amino-t-2-hydroxycyclohexaneacetate (13). On hea ting at 150-160°C and further reduction with lithium aluminum hydride of the resulting lactam, the 9-hydroxymorphan 14 was obtained. When reduction of 12 was carried out by catalytic hydrogenation in the presence of platinum oxide, the C_2 -epimer alcohol of 13 was obtained. However, its cyclization afforded the same lactam than that of 13, thus indicating that an epimerization is produced during the heating process.

Î

3. Phenylmarphans.

Once the nucleus of **2-azabicycla[3.3.l]nonane** was synthesized, the interest was focused on the preparation of 2-methyl-5-phenyl-2-azabicyclo^[3.3.1]nonanes, sin ce this type of substances possess the three structural features necessary for a compound to have an analgesic activity similar to morphine⁴. They are (a) a phenyl nucleus, (b) a quaternary carbon attached to this nucleus, and (c) a tertiary nitrogen two carbon atoms removed from the quaternary carbon.

The main problem of the first syntheses of morphans 18 (Ar=C₆H₅⁴³ and Ar= m -OHC₆H_A⁴⁴) was the low yield (20%) in the formation of 2-dimethylaminoethyl-2-aryl cyclohexanones 16 owing to the competition of the 0-alkylation process $(60\text{\textdegree})^{44}$, 45. The predominance of this process is probably due to steric hindrance to C-alkylation and to stabilization of the enolate of 15 by the aromatic nucleus. However, after House^{-s} studies on the factors as favoring C-alkylation⁴⁶, the synthesis was improved and 16b was formed from 15b in 40% yield using dimethylformamide, sodium hydride and 2-dimethylaminoethylchloride hydrochloride at room temperature. Since improved and <u>16b</u> was formed from <u>15b</u> in 40% yield using dimethylformamide, sodium
hydride and 2-dimethylaminoethylchloride hydrochloride at room temperature. Since
<u>15b</u> could be regenerated from enol ether <u>17b</u>, the interesting 34 .

The synthesis goes on^{43,44} converting 16a and 16b into their corresponding 6-bromoderivatives, later cyclization in basic media at room temperature, and dry distillation of the resulting ammonium salts. Finally, Wolff-Kishner reduction of

ketones 18a and 18b gave the phenylmorphan nucleus 19. Through the m-methoxyphenylderivative 19b, the corresponding phenol 19c and its acetylderivative were obtained 44 .

In an alternative synthesis of $19b^{34}$, alkylation of $15b$ with ethyl bromoacetate (sodium amide-ether) gave the C-alkyl product 20 in a 80% yield. Reduction of 20 with lithium aluminum hydride afforded (98%) a diol that, by oxidation under controlled conditions (chromic oxide, pyridine) gave (77%) the keto aldehyde 21. In tramolecular aldol condensation of 21 yielded (45%) a mixture of epimeric keto alcohols 22, Wolff-Kishner reduction of which (93%) followed by oxidation of the hydroxy function gave $(73\frac{1}{3})$ 1-m-methoxyphenylbicyclo $[3,2,1]$ octan-6-one (23) .

 $Ar = m-OCH₃C₆H₄$

Formation of its oxime (64%) and subsequent Beckmann rearrangement, criti cal step of this synthesis (8%), afforded the morphan nucleus 24. Methylation of 2 followed by reduction with diborane gave quantitatively phenylmorphan 19b.

Due to the strong pharmacologic action of $\binom{+}{1}$ -5-(m-hydroxyphenyl)-2-methyl morphan 19 c^{44} , the activity of both enantiomers, previously resolved with d-mandelic $\text{acid}^{34}, ^{47}$, was evaluated. They possess significant enantiomeric stereoselectivity in their biological actions. Thus, the levo isomer, an analgesic with morphine-like po tency, exhibits a weak narcotic antagonist activity and only a very slight physical dependence capacity⁴⁷. The $\frac{\text{dextr}}{\text{c}}$ isomer, four times more potent analgesic than mo<u>r</u> phine, has no antagonist activity and has a high physical dependence capacity $47,48$. The N-propyl, allyl, and cyclopropylmethyl derivatives of (+)-19c and its racemate were also prepared and their analgesic and antagonist activities studied⁴⁸. Later on, the absolute configuration of the analgesic agonist-antagonist (-)-19c was established²⁹ to be 1R, 5S by single-crystal X-ray analysis of its hydrobromide salt. Both rings of the 2-azabicyclo^[3.3.1] nonane system exist in chair conformations with the phenyl and methyl substituents equatorial.

On the other hand, the enantiomer $(+)$ - $19c$ was stereochemically correlated⁴⁹ with the normorphan $(+)$ - $(1R, 5S, 7R)$ -1- $(m-hydroxyphenyl)$ -6,7-dimethyl-6-azabicyclo $[3.2,1]$ octane (25c), compound of interest for its analgesic and antagonist properties. Thus, the methoxy derivative (-)-25b, a precursor of $(+)$ -25c, gave the olefin **(+)-a** as the sole product on Hofmann degradation. Hydroboration and subsequent oxidation of $(+)$ -26b afforded the carbinol $(+)$ -27b which through the respective chlo ride was turned into methochloride of morphan 19b. Dry distillation followed by 0demethylation gave a product identical in all respects to an authentic sample of the dextro isomer of phenylmorphan 19c. As in the process the configuration of the carbon bonded to the aromatic ring was not modified, this series of reactions provides an additional proof for the absolute configuration of normorphan $(+)$ -25c.

5-Phenylmorphans, with pharmacological Interest on their own,have been used when functionalized as intermediates in the synthesis of more elaborated pro ducts. Thus, a Knoevenagel reaction on ketone **3** allowed obtention of tetracyclic compound 28^{43,50}, a position isomer with respect to nitrogen attachment of N-methy¹ morphinan.

Likewise, 9-cis-amino-5-(m-methoxyphenyl)-2-methyl-2-azabicyclo^[3.3.1]nonane (29), prepared³² from ketone 18b, leads by Pictet-Spengler cyclization to the **tctracycllc system** *ip_32* **and by photolysis of its chloroacetamido derivative** 31 to 4,11b-propanopyrido^{[4},3-a] ^[3]benzazepine systems of type $\underline{32}^{51}$.

4. N-Chloramines route.

The first synthesis of a C-8 functionalized **2-azabicyclo[3.3.1]nonane** was described in 1970. It concerns the obtention of 2 -methyl-8-hydroxy-2-azabicyclo^{[3}. 3.1 nonane $(33)^{52}$, based on the easiness of N-chloramines for intramolecular addition to olefinic double bonds^{53,54}. To explain such reactions, the formation of ni trenium ions⁵⁵ via an heterolytic process in neutral protic media (methanol reflux or tetrahydrofuran-water in the presence of silver ion catalysis) was postulated. Functionalized 6 -azabicyclo^[3.2.1]octanes⁵⁴ have been prepared in these conditions. The procedure was not applicable to the synthesis of morphan **3352** and it was necessary to resort to a solvolysis in 1 M sulfuric acid. The mechanism differs in the sense that chloronium ions formed by ionization of chloramine 34 once protonated are now involved. Their addition to the double bond implies the formation of the cyclic chloronium cation 35, which when neutralizing the acidic aqueous reaction media would suffer a solvolysis with the formation of the diastereomeric epoxides
<u>36</u>.

Intramolecular opening of the epoxide ring of the **trans** isomer **3** yielded (37%) **2-methyl-8-hydroxy-2-azabicyclo[3.** 3. llnonane **(33)** , which was converted into **2-methyl-2-azabicyclo[3,3,1]nonane (6)** upon oxidation with Jones reagent, thioaceta lization of the resulting ketone 37, and subsequent Raney nickel desulfurization.

Alternatively, ketone 37 has been synthesized^{56,57} by intramolecular reaction under acidic conditions of an N-chloramine with the activated double bond of an enol ether, this reaction being already used in similar cyclizations 58 . The required en01 ether **38** was prepared in six steps from p-hydroxyphenylacetic acid in 27% overall yield. The corresponding N-chloramine was obtained by reaction of **38** with 1 M sodium hypochlorite solution, and by trifluoroacetic acid treatment it yielded a mixture (96%) of 37 and 40 in 4:1 ratio. The process involved again a chloronium ion addition to an activated double bond. When cyclization was carried out in methanol instead of pure trifluoroacetic acid, the formation in high yields of epimeric chloro ketals **39 was** described. These can be cyclized (73%) by acidic hydrolysis followed by base treatment to a **4:l** mixture of the eliminatian-cyclization product 40 and the ketone 37. Acid hydrolysis of the enol ether 40 afforded almost quantitatively the same ketone 37. Finally, marphan *5* was obtained by hydro genolysis^{56,57} of $\frac{37}{2}$ in acidic conditions with platinum oxide, the procedure having been described for some azabicyclic ketones⁵⁹.

The synthesis of ketone 37 has also been reported by cyclization of the Nchloramine corresponding to **38** in the presence of Lewis acids. The best yields (40- 50%) 60 were obtained with ZnX₂ type agents in methylene chloride at 0? The same ketone 37 was also obtained by cyclization of dioxolane 41 under acid solvolysis conditions (anhydrous trifluoroacetic acid-methanol solution) through an electrophilic

chlorination of the enol ether 42 formed from 41 and subsequent intramolecular dis placement of the halide 43 by the amino group. Thus, ketone 37 was obtained in 50% yield, together with the enol ether 40 $(10-30\text{m})$ ⁵⁷.

As it can be deduced from the methods reviewed in this section, the N-chlo ramines route permits to obtain only **C-8** functionalized **2-azabicyclo[3.3.l]nonanes.** Contrary to what it occurs in the 2-azabicyclo^[3.2.1]octane series⁵³ where the

bridghed carbon can be functionalized by this procedure, the application of this type of reactions as potential way to C-9 functionalized systems has been unsuc $cessful⁶¹$.

Thus, the silver nitrate catalyzed methanolysis of the N-chloramine 44 took place⁶¹ with formation of 7-substituted 1-methyl-cis-octahydroindole systems 5 and less than 1% of the desired **2-methyl-9-methoxy-2-azabicyc10[3.3.1]nonane** (46). On the other hand, N-chloramine 47 failed to cyclize to the expected azabicyclic ke tone 48, giving instead complex reaction mixtures 57 .

5. Intramolecular Michael-type cyclization.

The synthesis of *C-7* functionalized **2-azabicyclo[3.3.l]nonanes** can be achieved by means of an intramolecular Michael-type cyclization of an amine group upon an a,B-unsaturated ketone.

The synthesis^{62,63} of 6-azabicyclo^[3.2.1] octan-3-ones through an 1,4 intra molecular addition suggested two independent but analogous syntheses of Z-methyl- $2-azabzcclo[3.3.1]nonan-7-one (50, ReCH₃)$ ^{12,64}.

From diethyl 3-oxoglutarate, **3,5-dihydroxyphenylacetic** acid 51 was abtained⁶⁴, and hydrogenated (77% yield) to the dione <u>52</u> with rhodium on alumina in basic media at high temperature. The formation of amide 53 requires a laborious process. Treatment of 52 with two equivalents of isobutyl chloroformate did not only activa te the carboxyl group by forming a mixed anhydride but also protect the enolic hydroxyl as the carbonate ester. Subsequent treatment with benzylamine or methylamine, followed by hydrolysis of the intermediate carbonate and neutralization afforded the amides 53a and 53b, respectively, which were converted into enol ethers 54 with

methanol and p-toluenesulfonic acid. Reduction of 54 with lithium aluminum hydride in tetrahydrofuran gave the unisolated amino alcohols 55 which through acid hydrolysis followed by basic treatment yielded the desired 2-alkyl-2-azabicyclo[3.3.1]
nonan-7-ones (<u>50</u>) through the conjugated ketones <u>49</u>.

In the synthesis of Mitsuhashi and co-workers¹² from the same acid 51 the key intermediate *53* was obtained by an alternative way which avoids the formation of the amide group in the presence of the conjugated enolic system of 52. Thus, 3,5 dimethoxyphenylacetamides 57b and 57c were prepared from 51 by methylation with dimethyl sulfate, subsequent conversion of the resulting carboxylic acid (56) into the corresponding acid chloride and treatment with ammonia or methylamine. Reduction of 57 with sodium in liquid ammonia gave the dihydro derivatives 58. Hydrolysis of *58* with diluted hydrochloric acid afforded wantitatively the intermediate 53, from which the C-7 functionalized morphans 50b and 50c were prepared.

Condensation¹² of N-acetyl and N-formyl derivatives of 50 with 3-aminoacro lein gave the pyrido $\left[3,2-f\right]$ morphans 59 (R=COCH₇, CHO), (systematic name: 8-acyl-5,6, **7,8,9,10-hexahydro-5,9-methanopYrido[2,3-d]ocin)** This synthesis is the first approach to an heteromorphan system through a strategy which employed functionalized morphans. However, the carbonyl group at C-7 position confers ambiguity in the formation of the pyridine ring since the synthesis of 59 is accompanied by that of its structural isomer 60.

On the other hand, 2-methyl-2-azabicyclo^[3.3.1]nonan-7-one (50b) was converted³⁵ into a mixture of 2-methyl-2-azabicyclo^{[3}.3.1] non-6-ene (62) and its position isomer 63 through the hydroxyderivative 61. Thus, reduction of 50b with sodium borohydride gave stereoselectively the **endo** amino alcohol 61 whose dehydration (methanesulfonyl chloride in pyridine) afforded the olefins 62 and 63 , both of which upon catalytic hydrogenation were converted into **2-methyl-2-azabicyclo[3.3.1]nonane (6).** The 6,7 double bond in **62** is postulated to provide the n-electron density that **1s** usually imparted by the aromatic ring in 6,7-benzomorphans. However this replace ment of an aromatic ring by a single unsaturation does not result in compounds with significant analgesic activity.

6. Other syntheses with formation of piperidine ring in the last stage.

The unexpected formation of the azabicyclic system 67 when 3-methyl-2-cy clohexen -1-one (64) is treated with ethyl cyanoacetate and ammonia in alcohol, su ggested⁶⁵ the synthesis of 4-cyano-1-hydroxy-5-methyl-3-oxo-2-azabicyclo[3.3.1]nona ne (70) which is the first approach to **2-azabicyclo[3.3.1]nonane** systems with an alkyl substituent at C-5 position.

The lactam 67 probably results from an initial Knoevenagel condensation followed by Michael addition, ammonolysis of the resulting diester **65** and final cy clization by conjugated addition. Its hydrolysis and decarboxylation afforded **68** which later on was reduced with lithium aluminum hydride to give 5-methyl-2-azabi**cyclo[3.3.l]nonane-1-ethanol (69).** Likewise, when o,B-unsaturated ketone 64 was treated with cyanoacetamide in the presence of piperidine-water, the azabicyclo 70 was obtained in 77% yield.

Another approach to C-8 functionalized **2-azabicyclo[3.3.l]nonanes** involves a series of reactions different from the previously mentioned even through based on the same disconnections. This method consists in the formation of C_1 -N bond by intramolecular nucleophilic attack of an amide upon an epoxide in the presence of potassium tert-butoxide.

Thus, in model studies of the synthesis of the alkaloid echitamine, 2 **benzayl-Z-azabicycla[3.3.l]nonan-8-0ne** (74) was prepared and converted into the tetracyclic system 75 by Fischer indole synthesis³¹. Formation of alcohol 73 took place in 87% yield when the cyclization was achieved with the trans amido epoxide 72, and in 45% yield when the crude epoxide mixture resulting from epoxidation of the double bond of 71 was directly used. Oxidation to the ketone 74 took place in moderate yield (29%) with chromic acid in aqueous aceticacid.

A simllar strategy was used to synthesize **N-benzyl-2-azaadamantan-4-01** (76)" whlch could be formally considered as a rigid **2-azabicyclo[3.3.l]nonane** due to an additional carbon brldge between the 3 and 7 positions of the morphan nucleus

Photolysis of $\Delta^{5,6}$ -alkenylnitrosamines⁶⁶ in acidified methanol afforded satisfactorily azabicyclic nucleus of 6-azabicyclo^[3.2.1]octan-4-one type, either directly or through the respective oximes by a mechanism which involved aminium ra dicals⁶⁷. Their addition reactions to internal olefinic bonds are highly regiospe cific, and the procedure was extended, but with moderate yield, to the synthesis of the C-8 functionalized 2-azabicyclo^[3.3.1]nonane 37. In this case cyclization was carried out with the crude Δ^{6} ,⁷-alkenylnitrosamine 78 prepared from the secondary amine 77 previously used in the synthesis of these systems via chloramines. From the crude photolysate a 6% yield of morphan 37 together with a mixture of its E (16% yicld) and Σ (9% yield) oximes were isolated.

The picrate prepared from ketone 37 revealed hydroxyl absorptions at 3615 and 3345 cm^{-1} but not carbonyl absorption in its IR spectrum. This suggested that protonation ocurred at the carbonyl oxygen but not at the amine group as in $37a$.

7. Formation of carbocyclic ring in the last step: Dieckmann cyclization.

A new strategy in the synthesis of 2-azabicyclo^[3.3.1]nonan-8-ones was
the formation of the carbocyclic ring from a well substituted piperidine <u>via</u> a Dieckmann cyclization followed by decarbethoxylation. This way was adopted to **pre** pare 5,6,7,8,9,10-hexahydro-6,10-methanopyrido $\left[2,3-c\right]$ azocines $\left(79\right)^{33}$, since the presence of a β -keto ester moiety in the azabicyclo 83 was suitable for the subse quent elaboration of a pyridine ring.

The requisite piperidine *82* was prepared from 4-pyridineacrylic acid by esterification and hydrogenation to give ethyl 4-pyridinepropionate (80). Through the corresponding N-oxide and formation of a methoxy pyridinium salt, a cyano group was introduced, and in the same reaction media was hydrolyzed and esterified to ethyl 2-carbethoxy-4-pyridinepropionate (81). Catalytic hydrogenation over platinum oxide in acetic acid afforded the piperidine derivative 82 (R=H). Acylation of the secondary mine 82 with formic acetic anhydride or benzayl chloride and subsequent Dieckmann cyclizatian (sodium hydride-toluene) of the resulting acyl derivatives gave β -keto esters 83a and 83b respectively. Although the compound 83b reacted with hydrazine to give a pyrazolone derivative, the enolic character of the ketone group present in *83* prevented this system to react in Knoevenagel and Michael condensations or in the Reformatsky reaction. However, on hydrolysis with methanolic potassium hydroxide *83b* afforded in 78% yield **~-benzoyl-2-azabicyclo[3.3.1]nonan-8-one** (74) . Spectroscopic data of compound 74, specially the multiplicity of N-benzoyl signal in the nmr spectrum (δ 7.4, singlet) differs from those reported by Dolby³¹ $(67.1 - 7.8$, multiplet) for the same compound. The first agree with the observed magnetic equivalence of aromatic protons in dialkylbenzamides⁶⁸.

Treatment of ketone 74 with ethyl formate in the presence of sodium hydride gave the 8-keto aldehyde 84 which was subjected to a condensation with guanidine to yield the amino pyrimidine derivative 85 . Finally, pyridoazocine 79 (R=COC₆H₅) was prepared (57%) by treatment of 74 with 3-aminoacrolein in triethylamine in the presence of catalytic amount of ammonium acetate at 100-110°C, and from it, N-benzyl, N-formyl, N-H and N-methyl derivatives of 79 were described.

Through a Dieckmann cyclization of a suitably polysubstituted piperidine, a 2-azabicyclo^[3.3.1]nonan-6-one⁶⁹ which possesses a quaternary carbon in C-5 was obtained for the first time. Thus, monaalkylation of diethyl glutamate (86) with ethyl 4-bromobutyrate followed by benzoylation gave diethyl N-benzoyl-N-(3-carbethoxypropy1)glutamate *(3).* Ring closure of this triester was accomplished by the Dieckmann reaction with sodium ethoxide-benzene as cyclizing agent. The alkylation of 8-keto ester *89* (methyl iodide, potassium carbonate, acetone) led to a diastereomeric mixture 90 which, after conversion into the ethylenedithioketal **91** (boron trifluoride etherate, 80°C) and subsequent desulfurization (Raney nickel), was con verted into the diester 92, also in the form of diastereoisomeric mixture (1:1, glc). On standing, the trans isomer was obtained, and the resulting cis-enriched mixture was subjected to Dieckmann cyclizatian (sodium hydride, toluene) to give the desired functionalized **2-azabicyclo[3.3.l]nonane** system 93, which was decarbai koxylated to 94 by treatment with sodium chloride in wet dimethylsulfoxide (15S°C, 3 h).

These functionalized morphans are versatile intermediates for the elabora tion of condensed heterocyclic systems, and provide a new approach to the synthesis of heteromorphans. From β -keto ester 93, the pyrazolo $\lceil 3, 4-f \rceil$ morphan 95 was prepared. From ketone 94, the pyrido $[2, 3-f]$ morphan 96 by reaction with 3-aminoacrolein and indolo^{[2},3-f]morphan 97 by Fischer indole synthesis were prepared⁷⁰. In this hetero condensed morphans the heteroaromatic ring is fused unambiguously between the 6 and 7 positlon of the **2-azabicyclo[3.3.l]nonane** system, and they possess a methyl substituent on the carbon atom attached to the aromatic ring.

REFERENCES

- 1. In 1947 Barltrop suggested the denomination morphan for the 2-azabicyclo^[3.3.1]. nonane system.
- 2. M. Gates and G. Tschudi, J. Am. Chem. Soc., 78, 1380 (1956).
- 3. K. Nakanishi, T. Gata, S. Ito, S. Natori,and S. Nozoe, "Natural Products Chemis try", Vol. 11, Kodansha Scientific books, Tokyo, 1975, p. 255-422.
- 4. (a) E. L. My and L. J. Sargent, "Analgetics", ed. by G. de Stevens, Academic Press, New York, 1965; (b) J. Hellerbach, 0. Schnider, **M.** Besendorf, and B. Peli mant; N. B. Eddy and E. L. May, "Synthetic Analgesics", Part 11, Pergamon Press, Oxford, 1966. Oxford, 1966.
5. D. C. Palmer and M. J. Strauss, <u>Chem. Rev.</u>, 77,
- 77, 1 (1977).
- 6. J. Bosch, R. Granados, and F. López, J. Heterocyclic Chem., 12, 651 (1975).
- 7. T. A. Montzka and J. D. Matiskella, J. Heterocyclic Chem., 11, 853 (1974).
- 8. M. Alvarez, J. Bosch, R. Granados, and F. López, J. Heterocyclic Chem., 15, 193 (1978).
- 9. M. Alvarez, J. Bosch, and J. Canals, An. Quim., 71, 807 (1975).
- **10.** M. Alvarez, **.J.** Bosch, and M. Feliz, J. Heterocyclic Chem., E, **1089 (1978).**
- **11.** D. Kishore, P. K. Khandelwal] and B. C. Joshi, Arch. Sci., 27, **39 (1974).**
- **12.** J. Adachi, **K.** Nomura, and K. Mitsuhashi, Chem. Pharm. Bull., 24, **85 (1976).**
- **13.** J. Adachi, **K.** Nomura, S. Yamamoto, and K. Mitsuhashi, Chem. Pharm. Bull., 24, **2876 (1976).**
- **14. G.** C. Morrison, R. 0. Waite, A. N. Caro, and J. Shavel Jr., J. Org. Chem., **32, 3691 (1967).**
- 15. J. Bosch and F. Boncompte, An. Quim., 75, 357 (1979).
- **16. J.** Bosch, R. Granados, and R. Llohera, An. Quim., **75, 360 (1979).**
- **17.** J. Basch and D. Maule6n, unpublished results.
- **18.** R. J. Schultz, W. H. Staas, and L. A. Spurlock, J. Org. Chem., 38, **3091 (1973).**
- **19. G.** C. Morrison, R. 0. Waite, F. Serafin, and J. Shavel Jr., J. Orp. Chem., **32, 2551 (1967).**
- 20. G. C. Morrison, R. O. Waite, and J. Shavel Jr., J. Org. Chem., 32, 2555 (1967).
- **21. H.** Zinnes, **F.** R. Zuleski, and J. Shavel Jr., J. Org. Chem., 2, **3165 (1969).**
- **22.** M. Mokataff and L. J. Sargent, J. Org. Chem., **33, 3551 (1968).**
- **23.** J. A. Peters, Synthesis, **321 (1979).**
- **24. (a) T.** Momose and 0. Muraoka, Chem. Pharm. Bull., 3, **288, 2217, 2589 (1978);** (b) T. Momose, O. Muraoka, and S. Atarashi, Heterocycles, 12, 37 (1979).
- **25. G.** L. Buchanan, Chem. Soc. Rev., 2, **41 (1974).**
- **26. (a)** J. A. Marshall and H. Faubl, J. Am. Chem. Sac., *92,* **948 (1970);** (b) J. R. Wiseman and **IV.** A. Pletcher, **J.** Am. Chem. Soc., **z, 956 (1970);** (c) **K.** B. Becker, **Ilelv. Chim. Acta, 60, 81 (1977); (d) M. Kim and J. D. White, J. Am. Chem. Soc.,** - **99, 1172 (1977);** *(e)* H. 0. House, **W.** A. Kleschick and E. J. Zaiko, J. Org. Chem., - **43, 3653 (1978);** (f) K. J. Shea and S. Wise, J. Am. Chem. Soc., 100, **6519 (1978);** (g) K. Becker and R. W. Pfluger, Tetrahedron Letters, **3713 (1979).**
- **27.** M. Toda, H. Niwa, K. Ienaga, and Y. Hirata, Tetrahedron Letters, **335 (1972).**
- 28. (a) J. P. Schaeffer, J. C. Lark, C. A. Flegal, and L. M. Honig, <u>J. Org. Chem.</u>,
<u>32</u>, 1372 (1967); (b) J. A. Peters, J. M. Van der Toorn, and H. VanBekkun, Tetrahedron, 30, **633 (1974); (c) J.** A. Peters, Tetrahedron, 34, **3313 (1978);** (d) V. S. Mastryukov, M. V. Popik, O. V. Dorofeera, A. V. Golubinskii, L. V. Vilkov, N. **A.** Belikova, and N. L. Allinger, Tetrahedron Letters, **4339 (1979). 29. T.** G. Cochran, J. Med. Chem., 11, **987 (1974).**
- **30. (a) J.** R. Hargreaves and P. W. Hickmott, Tetrahedron, z, **3151 (1967);**
- (b) R. Gelin, S. Gelin, and R. Dolmazon, Bull. Soc. chim. France, 1049 (1973); (c) P. **W.** Hickmott, G. J. Miles, d. Sheppard, R. Urbani, and C. T. Yoxall, J. <u>Chem. Soc. Perkin I</u>, 1514 (1973); (d) D. Gravel and S. Rahal, <u>Can. J. Chem.</u>,
<u>53</u>, 2671 (1975).
- 31. L. J. Dolby and S. J. Nelson, J. Org. Chem., **38,** 2882 (1973).
- 32. H. Ong and E. L. May, J. Heterocyclic Chem., 8, 1007 (1971).
- 33. J. Adachi, K. Nomura, S. Shiraki, and K. Mitsuhashi, Chem. Pharm. Bull., 22, 658 (1974).
- 34. M. E. Rogers and E. L. May, J. Med. Chem., 17, 1328 (1974).
- 35. R. Cavestri and M. Makotoff, **J.** Med. Chem., 20, 1493 (1977).
- 36. J. A. Barltrop, J. Chem. Soc., 339 (1947).
- 37. E. Ferber and H. Bruckner, Chem. Ber., 76 , 1019 (1943).
	- 38. M. W. Cronyn, J. Org. Chem., 14, 1013 (1949).
	- 39. D. Ginsburg, J. Org. Chem., 15, 1003 (1950).
	- 40. J. H. Dygos, Diss. Abst. Int. B, 31, 3913 (1971); C. A. 76, 3668d.
	- 41. M. Toda, Y. Hirata, and S. Yamamura, Chem. Comm., 1597 (1970).
	- 42. F. Ramirez and J. W. Sargent, J. Am. Chem. Soc., 77, 6297 (1955).
	- 43. E. L. May and J. G. Murphy, J. Org. Chem., 19, 618 (1954).
	- 44. E. L. May and J. G. Murphy, J. Org. Chem., 20, 1197 (1955).
	- 45. J. G. Murphy and E. L. May, J. Org. Chem., 19, 615 (1954).
	- 46. H. 0. House, "Modern Synthetic Reactions" 2nd ed, W. A. Benjamin, Menlo Park, Calif., 1972, p. 520-526.
	- 47. E. L. May and M. Takeda, J. Med. Chem., 13, 805 (1970).
	- 48. H. H. Ong, T. Oh-ishi, and E. L. May, J. Med. Chem., 11, 133 (1974).
	- 49. M. Takeda, H. Inoue, K. Noguchi, Y. Honma, M. Kawamori, G. Tsukamoto, Y. Yama waki, S. Saito, K. Aoe, T. Date, S. Nurimoto, and G. Hayashi, **J.** Med. Chem.. - 20, 221 (1977).
	- 50. E. L. May, J. Org. Chem., 23, 947 (1958).
	- 51. H. H. Ong and E. L. May, J. Org. Chem., 37, 712 (1972).
	- 52. P. G. Gassman and J. H. Dygos, Tetrahedron Letters, 4749 (1970).
	- 53. P. Gassman, F. Hoyda, and J. H. Dygos, J. Am. Chem. Soc., **90,** 2716 (1968).
	- 54. P. G. Gassman and J. H. Dygos, Tetrahedron Letters, 4745 (1970).
	- 55. P. G. Gassman, Accounts Chem. Res., 3, 26 (1970).
	- 56. R. Tadayoni, A. Heumann, R. Furstoss, and B. Waegell, Tetrahedron Letters, 2879 (1973).
- 57. R. Furstoss, R. Tadayoni, G. Esposito, J. Lacrampe, A. Heumann, and B. Waegell, Can. J. Chem., 54, 3569 (1976).
- 58. A. Heumann, R. Furstoss, and B. Waegell, Tetrahedron Letters, 993 (1972).
- 59. (a) L. P. Reiff and H. S. Aaran, Tetrahedron Letters, 2329 (1967); (b) R. Furs toss, G. Esposita, P. Teissier, and B. Waegell, Bull. Soc. chim. France, 2485 (1974).
- 60. **J.** Lacrampe, A. Heumann, R. Furstoss, and B. Waegell, J. Chem. Res.(S), 334 (1978).
- 61. M. Mokotaff and R. R. Sprecher, Tetrahedron, **30,** 2623 (1974).
- 62. W. J. Gensler, C. **D.** Gatsonis, and Q. A. Ahmed, J. Org. Chem., 33, 2968 (1968).
- 63. R. Furstoss, P. Teissier, and B. Waegell, Chem. Comm., 384 (1970).
- 64. M. Mokotoff and R. C. Cavestri, J. Org. Chem., 39, 409 (1974)
- 65. M. W. Cronyn and G. H. Riesser, J. Am. Chem. Soc., 75, 1664 (1953).
- 66. Throughout this discussion the radical center will be designated as position 1.
- 67. R. A. Perry, S. C. Chen, B. C. Menon, K. Hanaya, and Y. L. Chow, Can. J. Chem., - 54. 2386 (1976).
- 68. V. I. Stenberg, S. P. Singh, and N. K. Narain, J. Org. Chem., *42,* 2244 (1977).
- 69. J. Bosch and J. Bonjoch, presented at the 1st European Symposium an Organic Chemistry, Cologne (1979).
- 70. J. Bosch and J. Bonjoch, unpublished results.

Received, 21st January, 1980